CONTEXT: NM404 is a second-generation radioiodinated phospholipid ether analog that undergoes prolonged and selective retention in a wide variety of malignant tumors in animal models. The compound takes advantage of an apparent lack of metabolic alkyl cleavage enzyme activity in tumor cells relative to normal cells. The aim of this project was to examine the tumor uptake and retention properties of NM404 in human non-small cell lung cancer (NSCLC).
RESULTS: Iodine-131-labeled NM404 was injected into patients with advanced NSCLC. The patients were scanned with a dual-head SPECT scanner at three, six, 24, 48, and 96 hours and at seven and 11 days. Qualitative imaging results indicated that I-131-labeled NM404 clearly localizes in bilateral pulmonary masses as early as 24 hours after injection and is selectively retained in the tumors for more than 11 days. Background radioactivity in the liver and lower abdominal region was significantly less than was observed previously with the predecessor agent NM324. No adverse reactions occurred in any of the patients.
IMPLICATIONS: The findings suggest that NM404 exhibits tumor uptake and retention properties in human NSCLC similar to those seen previously in rodent models. Efforts are under way to extend the utility of NM404 to PET imaging by incorporation with I-124, a positron isotope with a four-day half-life. Because of the selective and prolonged retention of NM404 in tumor cells, studies also are evaluating the radiotherapeutic potential of the agent.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.